News & Updates
Filter by Specialty:
Maternal TDF, infant HBV vax, HBIg-free strategy prevent infant hep B
In the absence of infant hepatitis B immune globulin (HBIg), maternal tenofovir disoproxil fumarate (TDF) prophylaxis combined with infant hepatitis B virus (HBV) immunization provide sufficient protection against HBV infection in infants, findings from the iTAP-2 study suggest. However, the risk of infection was not demonstrably below 2 percent.
Maternal TDF, infant HBV vax, HBIg-free strategy prevent infant hep B
01 Apr 2025
Prenatal BPG delivery: 9-day treatment interval linked to higher risk of congenital syphilis
When treating late latent syphilis during pregnancy, extending the interval between benzathine penicillin G (BPG) doses to 9 days may put newborns at risk of congenital infection relative to 6–8-day intervals, according to new research.
Prenatal BPG delivery: 9-day treatment interval linked to higher risk of congenital syphilis
23 Mar 2025
First HIV cure trial affirms tolerability of investigational combo in women with HIV
A phase IIa study affirms the tolerable safety of a combination regimen comprising three investigational compounds – two broadly neutralizing antibodies (bNAbs), VRC07-523LS and CAP256V2LS, and the TLR7 agonist vesatolimod – in women with HIV-1.
First HIV cure trial affirms tolerability of investigational combo in women with HIV
21 Mar 2025
Long-term oral progestogen therapy effective, well tolerated in endometriosis management
Endometriosis is a chronic disease, which requires interventions that are both effective and well tolerated in the long term. Dr Tak-Keung Sum, Specialist in Obstetrics and Gynaecology in private practice in Hong Kong, reviews clinical and real-world evidence on the long-term efficacy and safety of an oral progestogen, dienogest (Visanne®, Bayer), and shares his personal experience in managing endometriosis across different patient profiles.
